Introduction
The CCR5 receptor for the -chemokines RANTES (CCL5), MI-1 (CCL3), and MIP-1 (CCL4) is the primary co-receptor for β α β macrophage-tropic, non-syncytium inducing (NSI) strains of HIV-1 entry into CD4 cells . The CCR5 32, an allele that contains a
[1 ] Δ 32-base pair deletion encoding for a non-functional receptor, protects against infection in homozygotes patients and is associated with delayed disease progression and death in heterozygous untreated patients , , , .
[2 3 4 5 ]
Since 1996, the widespread use of combination antiretroviral therapy (cART) has improved the prognosis of HIV-1 infected patients [6 , . Several studies, whether immunological or virological, have focused on the association between CCR5 genotype and response to 7 ] cART,, at different time frames and have yielded controversial results , , , In the setting of the ANRS CO8 APROCO-COPILOTE cohort, we studied the association between the presence of the deletion and the virological response to cART up to 5 years.
Patients and methods

Patients
The ANRS CO8 APROCO-COPILOTE cohort is a prospective observational study that enrolled 1281 HIV-1 infected adults in 47 hospitals in France starting a protease inhibitor (PI)-containing antiretroviral regimen for the first time in 1997 1999 . Patients had - [18 ] physical and laboratory examinations at enrolment, after one and four months of cART, and every four months thereafter. Sera and cells were collected at enrolment and at follow-up visits. A DNA bank was set up in 2002 to study genetic factors associated with response to treatment or tolerability of the antiretroviral drugs. The study was approved by the Ethics Committee of Hospital Cochin and informed consent was obtained from all participants.
Methods
Polymerase chain reaction amplification of CCR5 sequences was done using genomic DNA extracted from cryo-preserved threshold of detection of 500 copies/ml at all measurements between month 4 (M4) and year 3, and between M4 and year 5. Patients experiencing only one plasma HIV-1 RNA above 500 copies/ml were considered as meeting the definition of sustained virological response in this analysis. Secondly, immunological response was assessed using the proportion of patients who achieved a CD4 cell count greater than 500/mm3 at year 3 and at year 5 . Both models were adjusted for the following baseline characteristics: HIV-1 RNA, CD4 [19 ] cell count, history of antiretroviral treatment at baseline (na ve cART) and during the follow-up (month 4 to year 3 and 5) (median 
RESULTS
Among 1281 patients initially enrolled in the cohort, 609 (48 ) participated in the genetic study set up in 2002. The reason for % non-participation was lost to follow-up or withdrawal from the cohort (n 259), death (n 84), refusal (n 51), inability to amplify (n 42) or
unknown (n 236). As the selection was important, we compared baseline characteristics according to whether patients were selected or not = for this study. Regarding CD4 cells count and undetectable HIV1-RNA at enrolment, no significant difference was noticed between these two groups. Regarding baseline CD4 cells count, participating patients had a median of 272/mm3 vs 277/mm3 among non participating patients (p 0.60). For HIV1-RNA, participating patients had a median of 4.5 copies/ml vs 4.5 copies/ml among non participating patients wt/wt, and none were homozygous. At baseline, as compared to wt/wt patients, 32/wt patients were less frequently born in Africa and Δ were older ( ). They had a lower median HIV-1 RNA and a higher but not significant CD4 cell count ( ). After adjustment for confounding factors, 32 deletion significantly associated with a sustained virological response during the period Δ M4 to 5 years post-enrolment (p 0.04), and a near significantly associated with a sustained virological response during the period from M4 = to 3 years post-enrolment (p 0.07)( ).
= Table 2 For immunological response 32 deletion was not a significant factor associated with a CD4 count greater than 500/mm3 at year 3 (p At baseline, patients with 32 deletion, were older, had higher CD4 cell count and lower HIV RNA than others. This might be Δ explained by the effect of CCR5 32 deletion on the natural evolution of HIV infection before these patients started cART. Indeed, Δ previous studies have shown that the presence of an allele with CCR5 32 confers a delayed progression to the HIV-1 disease in the Δ absence of cART , . Furthermore, the effect of the deletion may have contributed to a possible selection bias . Indeed, the patients [3 4 ] [19 ] who could be included in the genetic bank study were those who had survived from 1997 to 2002, and were younger. This bias limits the interpretation of our results, since only those with a better prognosis could be included.
Previous studies relating to the effect of virological response to cART according to CCR5-32 deletion provided contradictory Δ results: some found a protective role of the CCR5-32 deletion on virological response to cART , , , , , while others did Δ [8 9 10 11 16 17 ] not find any difference , , , . All have studied relatively short term response, no longer than 2 years. Moreover the [12 13 14 15 ] characteristics of the patients, clinical and biological status of HIV infection, geographical origin, whether they were pretreated or naive of cART, adherence to treatment, definition of the virological response (e.g 50 or 500 copies/ml) and time for assessment, varied among the studies.
Our study is probably the first to assess the impact of this deletion over a long follow-up of a large number of treated patients, and shows a significant better response after 5 years of treatment in the heterozygous patients. The longest follow-up was 24 months in the study of Bogner et al.
, which found a better virological response to cART, among adherent caucasian patients, na ve of antiretroviral [11 ] ï treatment.
The discrepancy between short-term and long-term virological response to cART in our study might explain some of the differences between previous studies. The interpretation of such a moderate effect of the deletion on response to cART would be in favour of either the absence of an effect among treated patients, or a limited effect only detectable after extensive follow-up. In order to take into account differences existing at baseline or occurring during follow-up that might also influence response to cART, the multivariable analysis was adjusted for potential confounders. Yet, we found that long term virological response was more pronounced in the heterozygous patients, reflecting a true independent effect of the CCR5 32 deletion in the context of a multifactorial determinism Δ of long term virological response. Therefore, the potential disadvantage of the innate wild-type profile might be counterbalanced by the beneficial effect of high adherence level and appropriate time for starting cART.
In view of conflicting results in the previous studies, a meta-analysis including other observational cohorts would bring more evidence on the long-term effect of this mutation.
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